General Catalyst-backed Fay landed the Series B fundraise at a valuation around $500 million.

India's Ministry of Health posted an anti-obesity ad on X, featuring a silhouette resembling Winston Churchill, causing speculation and online debate.

As many as 40% of Americans are obese, putting them at an increased risk for high blood pressure, diabetes, stroke, heart disease and certain cancers, according to the CDC. New research from the ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Neurons in the brains of mice tell them to stop eating when they’ve had enough food – and since people probably have the same ...

Although obese individuals are at greater risk of diabetes, high blood pressure or high cholesterol, not all obese people ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that ...

Both high-protein and low-carb diets are effective for weight loss. Consuming more protein may be the most important factor ...